Genotypic Influences on Network Progression in Parkinson's Disease

Updated on 1 February 2022
antiparkinsonian agents


The goal of this research study is to help scientists better understand how mutations in the GBA (glucocerebrosidase beta acid) gene affects patients with Parkinson’s disease. Mutations in the GBA gene are the most common genetic risk factors for Parkinson's, affecting about 10 percent of the more than 6 million people estimated to have the disease. 
Through prior research studies we have found patterns of brain activity that are common among patients with Parkinson’s disease (PD). This study will continue to investigate these patterns in patients with PD with a GBA mutation and patients with PD without the GBA mutation. We hope that this information will one day improve treatment for the disease.


Condition Parkinson's disease
Clinical Study IdentifierTX224549
Last Modified on1 February 2022


Yes No Not Sure

Inclusion Criteria

Diagnosis of PD made according to UK Parkinson’s Disease Society Brain Bank Criteria
Ability to provide written informed consent
Age 40-75
Stable dose of antiparkinsonian medication for >1 month prior to study entry

Exclusion Criteria

Subjects with pathogenic mutations in LRRK2
History of known causative factors such as encephalitis or neuroleptic treatment
Patients with dementia (defined as a Mini-Mental Status Exam score <24 or a Telephone Interview for Cognitive Status score <26)
Atypical parkinsonian features including myoclonus, apraxia, oculomotor abnormalities, incontinence, ataxia, sensory loss, or pyramidal signs
Known structural brain lesions
Patients with a history of stroke, head injury, high intracranial pressure or severe headaches
Psychiatric disorder, including a history of major depression in the past 36 months
Pregnant or breastfeeding women (female subjects of child-bearing potential will be screened for pregnancy before imaging)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note